IP Library › Granted Patent US 12,534,711
Granted Patent B2
US 12,534,711 · App. 18/741,089 · Granted Jan 27, 2026

Destabilising domains for conditionally stabilising a protein

Inventors: Mauno Vihinen (Lund, SE); Deniz Kirik (Lund, SE)
Assignee: BRAINGENE AB
C12N9/003C12N15/62C12Y105/01003A61K38/00C07K2319/02C07K2319/35
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,534,711
App. No.
18/741,089
Granted
Jan 27, 2026
Kind
B2
Abstract

The present disclosure relates to mutant polypeptides derived from Escherichia coli dihydrofolate reductase (DHFR) which can be fused to a polypeptide of interest for efficient conditional modulation of its activity. Also disclosed are polynucleotides encoding such mutant polypeptides, vectors comprising such polynucleotides, and the use of such polypeptides, polynucleotides and vectors for treating a disorder.

Claims (27)

1 . A fusion polypeptide comprising:

i) a mutant dihydrofolate reductase (DHFR) polypeptide selected from the group consisting of:

a) a mutant DHFR polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 with the exception of a single mutation selected from the group consisting of Y100E, M42A, and M42G, and

b) a mutant DHFR polypeptide comprising an amino acid sequence having 90% or greater amino sequence identity to the amino acid sequence of SEQ ID NO: 1 or having 90% or greater amino acid sequence identity to the amino acid sequence of SEQ ID NO: 2 and comprising a mutation in position W133,

wherein the mutant DHFR polypeptide is capable of binding to a DHFR inhibitor, and

ii) a polypeptide of interest,

wherein the mutant DHFR polypeptide is operatively linked to the polypeptide of interest,

wherein in the absence of said DHFR inhibitor said fusion polypeptide is destabilized as compared to a DHFR polypeptide consisting of the amino acid sequence of SEQ ID NO: 1, and wherein in the presence of said DHFR inhibitor, said fusion polypeptide is stabilized.

2 . The fusion polypeptide of claim 1 , wherein said mutant DHFR comprises the mutation at position W133.

3 . The fusion polypeptide of claim 1 , wherein the mutation in at position W133 at least partly removes the side chain at the mutated position.

4 . The fusion polypeptide of claim 1 , wherein the mutation in at position W133 is a mutation to a glycine (G) or to an alanine (A).

5 . The fusion polypeptide of claim 1 , wherein the mutant DHFR polypeptide is the Y100E single mutation.

6 . The fusion polypeptide of claim 1 , wherein the mutant DHFR polypeptide comprises a W133A mutation, a W133G mutation, a M42A single mutation, or M42G single mutation.

7 . The fusion polypeptide of claim 2 , wherein the mutant DHFR polypeptide further comprises a mutation in one or more of the positions R12, N18, D122, P126, D127, and/or F153.

8 . The fusion polypeptide of claim 2 , wherein the mutant DHFR polypeptide further comprises a mutation in one or more of the positions I50, R52, L54, and/or P55.

9 . The fusion polypeptide of claim 2 , wherein the mutant DHFR polypeptide further comprises one or more of the mutations: R12A, R12G, N18A, N18G, D122A, D122G, P126A, D127A, D127G, F153A and/or F153G.

10 . The fusion polypeptide of claim 2 , wherein the mutant DHFR polypeptide further comprises a mutation in a TMP binding pocket of the amino acid sequence of SEQ ID NO: 1.

11 . The fusion polypeptide of claim 2 , wherein the mutant DHFR polypeptide further comprises a mutation in one or more position M20, L28, F31, T46, S49, I50, and/or L54.

12 . The fusion polypeptide of claim 1 , wherein the mutant DHFR polypeptide is linked to the N terminus of the polypeptide of interest, and/or wherein the mutant DHFR polypeptide is linked to the C terminus of the polypeptide of interest.

13 . The fusion polypeptide of claim 1 , wherein the mutant DHFR polypeptide is further linked to a second polypeptide of interest.

14 . The fusion polypeptide of claim 1 , wherein the polypeptide of interest is a therapeutic polypeptide, a reporter polypeptide, an enzyme or a transcription factor.

15 . The fusion polypeptide of claim 13 , wherein the second polypeptide of interest is a therapeutic polypeptide, a reporter polypeptide, an enzyme or a transcription factor.

16 . The fusion polypeptide of claim 1 , further comprises a signal peptide capable of causing secretion of the fusion polypeptide from a mammalian cell or a nuclear localization signal capable of causing import of the fusion polypeptide in the nucleus of a cell.

17 . A system for conditionally stabilizing a fusion polypeptide comprising the fusion polypeptide of claim 1 and a dihydrofolate reductase (DHFR) inhibitor, wherein the DHFR inhibitor is capable of binding to the mutant DHFR polypeptide thereby stabilizing the fusion polypeptide, wherein the maximal activity of the polypeptide of interest in the presence of the DHFR inhibitor is at least 10-fold higher than in the absence of the DHFR inhibitor.

18 . The system of claim 17 , wherein the fusion polypeptide further comprises a reporter gene and wherein the activity of the polypeptide of interest is determine by measuring the activity of said reporter gene.

19 . The system of claim 17 , wherein the DHFR inhibitor is an antibiotic.

20 . The system of claim 17 , wherein the DHFR inhibitor is an anti-cancer drug.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2024
From: VIHINEN, MAUNO; KIRIK, DENIZ
To: BRAINGENE AB
Reel/Frame 068539/0042 →
Priority Claims (1)
SE 1650693-3 · May 20, 2016 · national
Continuity (3)
Continuation 17674220 · Feb 17, 2022
Continuation 16302897
Related Publication 20250019672A1 · Jan 16, 2025
References Cited (50)
US 4868116A · Morgan et al. · 1989 [cited by applicant]
US 5399346A · Anderson et al. · 1995 [cited by applicant]
US 5677158A · Zhou et al. · 1997 [cited by applicant]
US 6309634B1 · Bankiewicz et al. · 2001 [cited by applicant]
US 6451306B1 · Tuszynski et al. · 2002 [cited by applicant]
US 6683058B1 · Tuszynski · 2004 [cited by applicant]
US 20020037281A1 · Davidson et al. · 2002 [cited by applicant]
US 20090215169A1 · Wandless et al. · 2009 [cited by applicant]
US 20140010791A1 · Wandless et al. · 2014 [cited by applicant]
US 20170369870A1 · Gill et al. · 2017 [cited by applicant]
WO 9524929A2 · 1995 [cited by applicant]
WO 9530761A2 · 1995 [cited by applicant]
WO 2015152813A1 · 2015 [cited by applicant]
Murphy DJ et al. Hydrophobic Interactions via Mutants of [cited by examiner]
Lo K et al. High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells. 1998. Protein Engineering. vol. 11, No. 6. pp. 495-500. (Year: 1998). [cited by examiner]
Rajagopalan PTR et al. Interaction of dihydrofolate reductase with methotrexate: Ensemble and single-molecule kinetics. 2002. PNAS. vol. 99, No. 21. p. 13481-13486. (Year: 2002). [cited by examiner]
Siloto R et al. Site Saturation Mutagenesis: Methods and Applications in Protein Engineering. 2012. Biocatalysis and Agricultural Biotechnology. 1, 181-189. (Year: 2012). [cited by examiner]
Bachmair et al.; Science, vol. 234; 1986; pp. 179-186. [cited by applicant]
Banerji et al.; Cell, 1981; vol. 27; pp. 299-308. [cited by applicant]
Breathnach et al.; Ann. Rev. Biochem, 1981; vol. 50; pp. 349-383. [cited by applicant]
Capecchi et al.; Cold Spring Harbor Laboratories, 1991; pp. 101-102. [cited by applicant]
Corden et al.; Science, 1980; vol. 209; No. 4463; pp. 1406-1414. [cited by applicant]
De Wet et al.; J. Biol. Chem. 1983; vol. 258; No. 23; pp. 14385-14389. [cited by applicant]
Dohmen et al.; Science, 1994; vol. 263; No. 5151; pp. 1273-1276. [cited by applicant]
Fire et al.; Nature, 1998; vol. 391; pp. 806-811. [cited by applicant]
Gaffar et al.; Molecular & Biochemical Parasitology, 2004; vol. 133; pp. 209-219, fig. 2. [cited by applicant]
Iwamoto et al.; Chemistry & Biology; 2010; vol. 17; pp. 981-988. [cited by applicant]
Janse et al.; J. Biol. Chem., 2004; vol. 279: No. 20; pp. 21415-21420. [cited by applicant]
Jolly et al.; Nucleic Acids Res., 1983; vol. 11; No. 6; 1855-1872. [cited by applicant]
Kanemaki et al.; Nature, 2003; vol. 423; pp. 720-724. [cited by applicant]
Labib et al.; Science, 2003; vol. 288; pp. 1643-1646. [cited by applicant]
Matthews et al.; Methods in Enzymology, 1985; vol. 115; pp. 397-420. [cited by applicant]
Medema, Rene H.; Biochem. J., 2004; vol. 380; pp. 593-603. [cited by applicant]
Ohmae et al.; Journal of Biochemistry, 2001; vol. 130, No. 3; pp. 439-447. [cited by applicant]
Park et al.; Proc. Natl. Acad. Sci. U.S.A., 1992; vol. 89; pp. 1249-1252. [cited by applicant]
Prockop et al.; N. Eng. J. Med., 1984; vol. 311; No. 6; pp. 376-387. [cited by applicant]
Proudfoot et al.; The Journal of Biological Chemistry, 1989; vol. 264; No. 15; pp. 8764-8770. [cited by applicant]
Rossi et al.; Proc. Natl. Acad. Sci. USA, 1987; vol. 84; pp. 5590-5594. [cited by applicant]
Roth et al.; J Med Chem., 1987; vol. 30; No. 2; pp. 348-356. [cited by applicant]
Ryding et al.; J. Endocrinol., 2001; vol. 171; pp. 1-14. [cited by applicant]
Schmidt et al.; Nature, 1985; vol. 314; pp. 286-289. [cited by applicant]
Schneekloth et al.; J. Am. Chem. Soc., 2004; vol. 126; pp. 3748-3754. [cited by applicant]
Schnell et al.; Annu. Rev. Biophys. Biomol. Struct., 2004; vol. 33; pp. 119-140. [cited by applicant]
Schweitzer et al.; The FASEB Journal, 1990; vol. 4; pp. 2441-2542. [cited by applicant]
Smith et al.; Biochemistry, 1980; vol. 19; pp. 1820-1825. [cited by applicant]
Takahashi et al.; Epidemiology of Antimicrobial Resistance, 2002; vol. 51, pp. 510-515; abstract, fig. 1. [cited by applicant]
Tian et al.; PLOS Computational Biology, 2015; pp. 1-27; Abstract, table S1. [cited by applicant]
Weiss et al.; Cold Spring Harbor Laboratory, 1982. [cited by applicant]
Yao Fan et al.; Biochemistry, 2013; vol. 52; No. 12; pp. 2036-2049. [cited by applicant]
Medema, et al.; Biochem. J. 2004; 380: p. 593-603. [cited by applicant]